Analyst Price Targets — NEUP
Page 1 • Showing up to 10
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 5, 2025 12:43 pm | — | H.C. Wainwright | $7.00 | $4.27 | TheFly | Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright |
×
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for NEUP

Critical Analysis: Immunic (NASDAQ:IMUX) and Neuphoria Therapeutics (NASDAQ:NEUP)
Immunic (NASDAQ: IMUX - Get Free Report) and Neuphoria Therapeutics (NASDAQ: NEUP - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Profitability This table compares Immunic and Neuphoria Therapeutics'
Defense World • Mar 4, 2026
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NEUP.
U.S. House Trading
No House trades found for NEUP.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Bid/Ask/Mark (first):
Core Metrics:
More Greeks (optional):
Valuation:
Price & Momentum:
IV Variants:
IV Units:
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
